Montana should lead the charge For PTSD treatments
Post-traumatic stress disorder (PTSD) is a scary reality facing 13 million Americans, acutely affecting veterans who risked their lives to serve our country and resilient survivors of sexual assault and domestic abuse.
Helping these individuals find relief where they can is imperative and one federal agency is considering action that could do just that.
The U.S. Food and Drug Administration (FDA) is set to vote on the approval of MDMA-assisted therapy (MDMA-AT) to treat PTSD in the next few days. Unlike the only two drugs currently on the market to treat this illness that do nothing to actually address the root cause of the disease, MDMA-AT actually has the potential to help patients overcome the root cause of their diagnosis and it’s backed by science.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
